Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025 - 2The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- 3The Manual for Decent European Urban communities in 2024
- 4Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 5Explainer-What has happened to the damaged spacecraft at China's space station?
- Passenger Missing After Going Overboard Disney Cruise Ship
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
- Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Top 10 Books That Will Have an impact on Your Viewpoint
- Dick Van Dyke shares his secrets to longevity as he turns 100
- I read 115 books this year. 'Wuthering Heights,' 'Heart the Lover' and 'The House of My Mother' were among my 10 favorites.
- Most loved Solace Food: What's Your Definitive Comfortable Dinner?
- Italy now recognizes the crime of femicide and punishes it with life in prison
